Luessen comes to Promethera as the founder and Managing Director of consultancy Tytonis B.V., The Netherlands. In the past, Luessen was involved in the foundation to trade sale of several life science firms such as Symbiotec GmbH, Nanomi B.V. and Activaero GmbH. He also served CBO at OctoPlus NV until its IPO in 2006. During his time at OctoPlus, Henrik commercially developed the company from a group of 12 employees with a core expertise in pharmaceutical development services of biopharmaceutical compounds to an organization of 140 people with two proprietary products in clinical development. Luessen obtained his Ph.D. in Pharmaceutics and Biopharmaceutics from the Leiden/Amsterdam Center for Drug Research in 1996 and graduated at the University of Hamburg as Pharmacist in 1991.

At the same time, Promethera has also appointed Nancy Veulemans as VP Clinical & Medical Affairs and Decebal Bora as VP Regulatory Affairs.